Rodrigo Dienstamann
Principal Investigator
Oncology
Vall d'Hebron Institut d’Oncologia
Spain
Biography
Dr. Rodrigo Dienstamann is currently working as a Principal Investigator, Oncology Data Science (ODysSey) Group in the Department of Oncology, Vall d'Hebron Institute of Oncology , Spain. His research interests includes cancer therapy, genomics, computational oncology. He is serving as an editorial member and reviewer of several international reputed journals. Dr. Rodrigo Dienstamann is the member of many international affiliations. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to cancer therapy, genomics, computational oncology.
Research Interest
Integration of clinical and translational research with genomics for precision cancer therapy Clinical-molecular databases of matched targeted agents and standardized reports of next-generation sequencing tests. Collaborative research in cancer genomics/computational oncology and its clinical implications
Publications
-
Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Doisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors.Target Oncol. 2016;11(2):149-56.
-
Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Mol Cancer Ther. 2016;15(5):1106-12.
-
Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016;22(3):644-56.
